OPT Congress
OPT Congress
  • Do-it-again

OPT BOSTON 2017 Grows by 43% in 2017! Attended by more than 140 unique companies

The Second Annual “Oligonucleotide & Peptide Therapeutics Boston” (OPT BOSTON) was held March 27-29, 2017 at the Royal Sonesta Boston, in Cambridge, Massachusetts.

More than 200 industry leaders from 17 different countries joined the 3 day discussions covering important issues related to the advances in the discovery, development and delivery of next-generation oligonucleotide and peptide therapies. This three-day event included two main conferences covering topics within discovery, clinical development, delivery, formulation and manufacturing, as well as two symposia focused on applications within oncology and immunotherapy.

The congress grew in attendance by 43% over last year. Also, Participation was represented well with 36% attended by executives. With more than 60% of the audience from biotech, another 20% from pharma, and the event represented by 140+ unique organizations, this event will continue to gather a diverse body of attendees from around the world to network, share ideas, and discuss cutting-edge science and technology.


2017 Event Features

  • 200+ Participants
  • 2 Conferences
  • 2 Symposia
  • 2 Dinner Courses
  • Dedicated Exhibit Hall Hours and Networking Functions

2017 Programs

March 27-28

  • Oligonucleotide Discovery and Development
  • Peptide Discovery & Development

March 29

  • Symposia: Oligonucleotides for Cancer Immunotherapy
  • Symposia: Peptides in Cancer Therapy

Hear what people had to say about this year’s event

“It was my first time attending the show, and I was very impressed with the variety of speakers and content”

Chris M., Ph.D. , Director, Business Development , Bachem Americas, Inc.

"This three-day meeting combines frontier works from both academic and industry which truly illustrated the current status of oligonucleotides therapeutics."

Patrick L., Ph.D., President & CEO, Sirnaomics, Inc.

“No events go without a hitch, but your crack team met all the obstacle head on, to our complete satisfaction. We’ve already signed up for the next event”

Rick N., President, Oligo Factory

"Great learning event"

Dr. Miriam K., CSO & Director, Oramed Pharmaceuticals, Inc.

Key Contacts

For content and speaker suggestion

Oligonucleotide Discovery and Development
Kip Harry
Senior Director, Conferences
Cambridge Healthtech Institute
T: 781.972.5454
E: kharry@healthtech.com

For partnering and sponsorship information:

Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
T: 781-972-5412
E: cbenton@healthtech.com

For content and speaker suggestion

Peptide Discovery and Development
Dan Barry
Senior Director, Conferences
Cambridge Healthtech Institute
T: 781.972.1360
E: dbarry@healthtech.com

For media partnerships:

Rich Handy
Senior Director, Marketing
Cambridge Healthtech Institute (CHI)
T: (+1) 781-972-5456
E: rhandy@healthtech.com

Track 1 Oligonucleotide Discovery and Delivery  
Track 2 Peptide Discovery and Development  

Symposia 1 Oligonucleotides for Cancer Immunotherapy
Symposia 2 Peptides in Cancer Therapy


Short Courses